Tonya Villafana - AstraZeneca-澳门葡京网赌游戏

结合我在免疫学方面的学术训练和公共卫生方面的经验, 我负责领导疫苗和单克隆抗体的跨职能全球产品开发团队. This includes, but is not limited to, AZD1222(针对SARS-CoV-2的ChAdOx1-S疫苗)和MEDI8897(针对呼吸道合胞病毒的尼瑟维单抗).

作为传染病的全球特许经营主管和全球产品主管, I work within BioPharmaceuticals R&D .探索在全球最脆弱人群中预防或治疗传染病的潜在新疫苗和药物. 我在全球范围内与一些重要的外部利益攸关方密切合作, including public health organisations, regulatory authorities, 与政府代表和医疗保健政策制定者讨论从早期开发到产品发布的关键发展里程碑.

During my career, 我曾在几个科学委员会和咨询委员会任职，包括疟疾临床试验联盟, 国际疫苗协会和美国国立卫生研究院综合临床前/临床艾滋病疫苗开发计划. I have worked closely on global health initiatives with the World Bank, the Bill and Melinda Gates Foundation, PAHO, WHO, IFPMA, and the UK Development Agency for International Development. I have been fortunate to work in countries around the world, 在高收入和低收入环境下，这使我对如何最好地满足不同人群的需求有了重要的看法.

我获得了威尔康奈尔大学医学科学研究生院的免疫学博士学位和哈佛大学公共卫生学院的公共卫生硕士学位.

克服传染病带来的挑战需要先进的科学与以社区为中心的方法相结合. 澳门葡京网赌游戏的价值观与此密切相关，这就是澳门葡京赌博游戏如何在全球范围内产生如此巨大的影响.

Tonya Villafana Vice President, Global Franchise Head, Infection

Award

Featured Speaker, Women and Science Program, Wistar Institute, 2017

Award

国际奖，艾滋病毒疫苗试验网络年度站点主任，2004年

Award

2003年，法国韦里耶湖梅里埃基金会第四届高级疫苗学研修班奖学金

Award

Jack and Susan Rudin Scholar, Weill Cornell University Graduate School of Medical Sciences, New York, NY 1992-1998

IFPMA World Bank Fellow and secondment from AstraZeneca

借调到世界银行，支持药品政策倡议和全球药品监管协调倡议，以加强非洲的监管体系(2011-2013年)

Director, Malaria Vaccines Initiative, PATH

Director, Portfolio Management, PATH MVI oversight of MVIs vaccine portfolio and member of the RTS,S Team (2006-2009)

Director, 博茨瓦纳哈佛艾滋病毒研究和教育伙伴关系(哈佛公共卫生学院)

与美国国立卫生研究院艾滋病毒疫苗试验网络合作建立临床站点，在博茨瓦纳开展首批艾滋病毒疫苗研究(2001-2006年)

Featured publications

Voysey M, Costa Clemens SA, Madhi SA et al; Oxford COVID Vaccine Trial Group. 单剂给药及加强剂量时间对ChAdOx1 nCoV-19 (AZD1222)疫苗免疫原性和疗效的影响:4项随机试验的汇总分析. Lancet. 2021 Feb 19:S0140-6736(21)00432-3. doi: 10.1016/S0140-6736(21)00432-3.

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3/fulltext

ChAdOx1 nCoV-19疫苗(AZD1222)抗SARS-CoV-2的安全性和有效性:巴西四项随机对照试验的中期分析, South Africa, and the UK. Voysey M, Clemens SAC, Madhi SA et al. Lancet. 2021 Jan 9;397(10269):99-111.

http://www.sciencedirect.com/science/article/pii/S0140673620326611?via%3Dihub

Ramasamy MN, Minassian AM, Ewer KJ, et al; Oxford COVID Vaccine Trial Group. ChAdOx1型nCoV-19疫苗在年轻人和老年人中的安全性和免疫原性(COV002):单盲研究, randomised, controlled, phase 2/3 trial. Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1.

http://www.sciencedirect.com/science/article/pii/S0140673620324661?via%3Dihub

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. Griffin MP, Yuan Y, Takas T et al. N Engl J Med. 2020 Jul 30;383(5):415-425.

http://www.nejm.org/doi/full/10.1056/NEJMx200019

血清阳性人群疫苗I期研究免疫原性数据分析的广义ROC方法. Yu L, Esser MT, Falloon J, Villafana T, Yang H. Hum Vaccin Immunother. 2018;14(11):2692-2700.

http://www.tandfonline.com/doi/full/10.1080/21645515.2018.1489191

Domachowske JB, Khan AA, Esser MT, Jensen K, Takas T, Villafana T, Dubovsky F, Griffin MP. Safety, Tolerability and Pharmacokinetics of MEDI8897, 延长半衰期单剂量呼吸道合胞病毒预融合f-靶向单克隆抗体单剂量给予健康早产儿. Pediatr Infect Dis J. 2018 Sep;37(9):886-892. doi: 10.1097/INF.0000000000001916.

http://journals.lww.com/pidj/Fulltext/2018/09000/Safety,_Tolerability_and_Pharmacokinetics_of.9.aspx

2016- 2017年美国冬季病毒季OUTSMART-RSV监测项目中流行RSV毒株的特征
Ruzin A, Pastula ST, Levin-Sparenberg E, Jiang X, Fryzek J, Tovchigrechko A, Lu B, Qi Y, Liu H, Jin H, Yu L, Hackett J, Villafana T, Esser MT. PLoS One. 2018 Jul 24;13(7):e0200319.

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0200319

低收入和中低收入国家的疫苗开发和试验:关键问题, advances and future opportunities. Grenham A, Villafana T. Hum Vaccin Immunother. 2017 Sep 2;13(9):2192-2199.

http://www.tandfonline.com/doi/full/10.1080/21645515.2017.1356495

Villafana T, Falloon J, Griffin MP, Zhu Q, Esser MT. 针对年轻人和老年人的呼吸道合胞病毒被动和主动免疫. Expert Rev Vaccines. 2017 Jul;16(7):1-13. doi: 10.1080/14760584.2017.1333425. Epub 2017 Jun 7.

http://www.tandfonline.com/doi/abs/10.1080/14760584.2017.1333425?journalCode=ierv20

A phase 1a, first-in-human, 有或没有toll样受体-4激动剂和稳定乳剂佐剂的呼吸道合胞病毒F蛋白疫苗的随机研究
Falloon J, Ji F, Curtis C, Bart S, Sheldon E, Krieger D, Dubovsky F, Lambert S, Takas T, Villafana T, Esser MT. Vaccine. 2016 May 27;34(25):2847-54.

http://www.sciencedirect.com/science/article/pii/S0264410X16301220?via%3Dihub